Aeterna Zentaris will present the final phase II  results in endometrial cancer on its anticancer compound, AEZS-108, during a poster session at the upcoming 17th International Meeting of the European Society of Gynaecological  Oncology ("ESGO"), Sept. 11-14 in Milan, Italy.

The trial was conducted by the German AGO Study Group and study centers in Bulgaria. AEZS-108, a targeted cytotoxic peptide conjugate, is currently in phase I/II programs in prostate and bladder cancer, and has successfully completed phse II trials in endometrial and ovarian cancer.

AEZS-108 represents a new targeting concept in oncology using a hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin. Phase II studies for the treatment of endometrial and ovarian cancer have been successfully completed, and phase I/II trials are being conducted in prostate and bladder cancer. AEZS-108 is the first intravenous drug in a clinical study that directs the chemotherapy agent specifically to LHRH-receptor expressing tumors, resulting in more targeted treatment with less damage to healthy tissue. AEZS-108 has been granted orphan-drug designation by the FDA and orphan medicinal product designation from the EMA for the treatment of ovarian cancer.